Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial

Keyphrases

• Anterior Insula 12%
• Antidepressants 37%
• Arterial Spin Labeling 25%
• Behavioural Predictors 12%
• Biomarker Predictors 12%
• Biosignatures 12%
• Brain Regions 37%
• Cerebral Perfusion 100%
• Clinical Care 25%
• Clinical Efficacy 12%
• Clinical Outcome Prediction 12%
• Clinical Predictors 12%
• Composite Moderator 37%
• Default Mode 12%
• EMBARC 100%
• Error Process 12%
• Fusiform 12%
• Inferior Parietal Lobule 12%
• Inferior Temporal Gyrus 12%
• Large Trials 12%
• Linear Mixed Model 12%
• Major Depressive Disorder 100%
• Medical Center 12%
• Middle Frontal Gyrus 12%
• Moderation Analysis 25%
• National Institute of Mental Health 12%
• Neuroimaging 12%
• Orbital Frontal 12%
• Parahippocampus 12%
• Perfusion 87%
• Perfusion Pattern 25%
• Placebo 100%
• Predictors of Treatment Response 12%
• Putamen 12%
• Randomized Placebo-controlled Trial 12%
• Remission Rate 50%
• Response Predictors 100%
• Resting-state Brain Activity 12%
• Reward Salience 12%
• Sertraline 100%
• Treatment Response 25%
• Treatment Selection 25%
• Trial Registration 12%
• Trial-and-error 12%
• Voxel-wise 12%
• Whole Brain 12%

Medicine and Dentistry

• Anterior Insula 12%
• Antidepressant 37%
• Arterial Spin Labeling 25%
• Biological Marker 12%
• Brain Function 12%
• Brain Region 37%
• Frontal Gyrus 12%
• Inferior Parietal Lobule 12%
• Inferior Temporal Gyrus 12%
• Major Depressive Episode 100%
• Mental Health 12%
• Placebo 100%
• Putamen 12%
• Sertraline 100%
• Spontaneous Remission 50%
• Treatment Response 37%

Neuroscience

• Antidepressant 37%
• Arterial Spin Labeling 25%
• Brain Function 12%
• Gyri 12%
• Inferior Parietal Lobule 12%
• Inferior Temporal Gyrus 12%
• Major Depressive Disorder 100%
• Placebo 100%
• Putamen 12%
• Sertraline 100%